PTPN2 Expression in Cystadenocarcinoma Ovary and It’s Clinical Value Based on TCGA Database
Abstract Ovarian serous cystadenocarcinoma (OV) is a malignant tumor that often has a poor prognosis because of its late detection. The expression of PTPN2 is associated with a variety of tumors, but its effect on OV is not well understood. Therefore, we analyzed the relationship between PTPN2 and the prognosis of OV. Analysis of patients with OV using The Cancer Genome Atlas revealed an association between PTPN2 expression and the prognosis of OV. We established a model of the relationship between these factors by logistic regression, which showed a significant correlation between the tumor grade and decreased expression of PTPN2. Kaplan-Meier survival analysis showed that low PTPN2 expression was associated with poor overall survival. Further analysis of the expression of immune cells in OV using the ssGSEA package revealed a significant correlation between the expression level of PTPN2 in OV and the numbers of mast, gamma delta, helper, and central memory T cells. We also found differences between the phenotypic pathways associated with low PTPN2 expression and pathways of genes and proteins that determine epithelial-mesenchymal transformation. Finally, a network diagram of protein molecular interactions was drawn using the STRING database, which showed that PTPN2 was closely related to the signal converter and transcriptional activator family and Janus kinase family. Thus, PTPN2 shows potential for use as a prognostic biomarker in OV and is associated with immune infiltration.